Inhibition of melanoma metastasis by dual‐peptide PLGA NPS

Arruda, Denise C.; Oliveira, Thaís Dolzany de; Cursino, Patrícia Harume Fukuda; Maia, Vera; Berzaghi, Rodrigo; Travassos, Luiz R.; Tada, Dayane Batista

doi:10.1002/bip.23029

Cited by 19 publications

(8 citation statements)

References 21 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA NPs without any encapsulated molecule were prepared by using a single emulsion-solvent evaporation method as described elsewhere [27]. Firstly, an organic solution of 100 mg of PLGA in 4 mL of DMF was prepared.…”

Section: Synthesis Of Plga Npsmentioning

confidence: 99%

Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer

et al. 2021

View full text Add to dashboard Cite

The development of resistance against photodamage triggered by photodynamic therapy (PDT) is ascribed mainly to the cellular redox defenses and repair. If the tumor tissue is not promptly eliminated by the first few PDT sessions, PDT-resistance can be favored, challenging the efficacy of the treatment. Although the mechanism of PDT resistance is still unclear, in vitro assays have evidenced that it can be developed through the PARP damage-repair signaling pathway. Therefore, inhibition of poly(adenosine diphosphate (ADP)-ribose) polymerase (PARP) has the potential to increase PDT efficacy. This work reports on the synthesis of a controlled release system of a photosensitizer, methylene blue (MB) and a PARP-inhibitor, the veliparib. MB and veliparib were co-encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (VMB-NPs). A colloidal stable aqueous suspension of nanoparticles was obtained. The average hydrodynamic diameter was 90 nm and a narrow size distribution was obtained, with a polydispersity index (PDI) of 0.08. The release kinetics of MB and veliparib from VMB-NPs showed an initial burst of 8.7% and 58.3% release of the total amounts of MB and veliparib respectively, in the first 6 h, and a delayed release of up to 11.3% and 70%, in 19 days, for MB and veliparib, respectively. The VMB-NPs showed no cytotoxicity in the dark but the viability of B16F10-Nex2 cells decreased by 36% when the cells were irradiated (102 J/cm2, 660 nm) and treated with VMB-NPs containing 1.0 µM of MB and 8.3 µM of veliparib. Considering the increased photoactivity even at low MB and veliparib concentrations and the absence of cytotoxicity in dark, the co-encapsulation of MB and veliparib was shown to be a promising strategy to improve the PDT efficacy.

show abstract

Section: Synthesis Of Plga Npsmentioning

confidence: 99%

Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[360] [353] Salinomycin Anti-CD20 aptamers Specific binder targeting (CD20 is is a marker of melanoma-initiating cells)…”

Section: Multifunctional Delivery Systemsmentioning

confidence: 99%

Nanotechnology approaches in the current therapy of skin cancer

Borgheti-Cardoso

Viegas

Silvestrini

et al. 2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Skin cancer is a high burden disease with a high impact on global health. Conventional therapies have several drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the challenges of skin cancer therapy. Then, the main features of developing efficient nanosystems will be discussed, and next, the most commonly used nanoparticles (NPs) described in the literature for skin cancer therapy will be presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, multifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface functionalization will be summarized.

show abstract

“…In the last period, several publications highlighted the efficiency of PLGA-NPs in delivering anticancer agents; in a recent work, Arruda and his co-workers showed that the encapsulation of a peptide with antitumoral activity, P20 (CSSRTMHH), within the PLGA-NPs conjugated to the C peptide with a homing function (CVNHPAFACGYGHTMYYHHYQHHL), strongly increases their functionality. The therapeutic effect of these NPs was evaluated in a syngeneic model of metastasis and was shown to produce the same inhibitory effect of free P20 at fivefold higher concentration, reducing by 28% the number of lung nodules [ 21 ].…”

Section: Nanoparticles and Drug Deliverymentioning

confidence: 99%

Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis

Arasi

Pedini

Valentini

et al. 2020

Cancers

View full text Add to dashboard Cite

Advanced melanoma is still a major challenge in oncology. In the early stages, melanoma can be treated successfully with surgery and the survival rate is high, nevertheless the survival rate drops drastically after metastasis dissemination. The identification of parameters predictive of the prognosis to support clinical decisions and of new efficacious therapies are important to ensure patients the best possible prognosis. Recent progress in nanotechnology allowed the development of nanoparticles able to protect drugs from degradation and to deliver the drug to the tumor. Modification of the nanoparticle surface by specific molecules improves retention and accumulation in the target tissue. In this review, we describe the potential role of nanoparticles in advanced melanoma treatment and discuss the current efforts of designing polymeric nanoparticles for controlled drug release at the site upon injection. In addition, we highlight the advances as well as the challenges of exosome-based nanocarriers as drug vehicles. We place special focus on the advantages of these natural nanocarriers in delivering various cargoes in advanced melanoma treatment. We also describe the current advances in knowledge of melanoma-related exosomes, including their biogenesis, molecular contents and biological functions, focusing our attention on their utilization for early diagnosis and prognosis in melanoma disease.

show abstract

Inhibition of melanoma metastasis by dual‐peptide PLGA NPS

Cited by 19 publications

References 21 publications

Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer

Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer

Nanotechnology approaches in the current therapy of skin cancer

Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis

Contact Info

Product

Resources

About